Signal Breakdown
7 verified publisher articles from recent coverage.
Limited TV coverage this week.
Limited video coverage this week.
GDELT tone + context across verified sources.
What’s Driving Sentiment
Bullish Signals
- No current bullish signals listed.
Risk Factors
- Upcoming earnings will be watched for margins, any update on the paused Astral ventilator program, and progress on a proposed software divestment.
- Analyst consensus is an average 'Hold' with a $243.23 12‑month price target, signaling limited near‑term upside.
- An ASX update flagged delivery, sector conditions, and commercial activity as market focus areas, highlighting demand uncertainty.
- A ResMed officer sold 400 shares under a Rule 10b5‑1 plan, which may be viewed by some investors as minor insider liquidity pressure.
Evidence
- 2026-10-27Source: TIINGO
Summary: ResMed Global General Counsel Michael Rider sold 400 RMD shares at $255.00 apiece under a pre-established 10b5-1 plan, netting about $102,000—appears to be routine insider liquidity rather than a material company development.
Neutral - 2026-10-27Source: TIINGO
Summary: ResMed issued a company update emphasizing execution and capital discipline; the market's view will be influenced by subsequent evidence, with no specific financial details provided in the brief summary.
Neutral - 2026-10-26Source: TIINGO
Summary: ResMed insider Michael J. Rider sold 400 RMD shares at $255.00 each on October 23, 2026; a small insider sale that offers limited insight into company outlook without additional context.
Neutral - 2026-10-25Source: TIINGO
Summary: ResMed will report later this week; investors will monitor margins, any update on the paused Astral ventilator program, progress on software divestment, and effects of weight‑loss medication trends on sleep‑apnea demand.
Neutral - 2026-10-24Source: TIINGO
Summary: ASX update flagged delivery, sector conditions and commercial activity as drivers of market focus on ResMed (ASX:RMD); the brief item gives no specific financial figures or guidance, leaving implications for revenue or stock direction unclear.
Neutral - 2026-10-24Source: TIINGO
Summary: Sixteen analysts rate ResMed (RMD) an average ‘Hold’ with a $243.23 twelve-month price target; nine analysts give a Hold and seven give a Buy, per MarketBeat.
Neutral - 2026-10-23Source: TIINGO
Summary: ResMed officer Michael J. Rider intends to sell 400 shares under a Rule 10b5-1 plan. This routine, small-scale insider sale is unlikely to materially affect ResMed’s outlook or stock performance.
Neutral
Showing 7 of 7 verified news articles
- No current evidence is available for this source.
No current verified Archive TV segments
- No current evidence is available for this source.
No verified video evidence in the current 7-day window
Formula & Methodology
- News
- GDELT discovers coverage; only publisher passages that directly name the company qualify as news evidence.
- TV
- Internet Archive TV captions are retained only with a match-centered quote that directly names the company.
- Video
- Recent Bullish Gator videos tagged to the company; the item summary and publisher label feed the judge.
- Holistic AI judge
- A single Azure OpenAI call reads the news, television, and video evidence together and returns the rating, a 0–100 composite, and a short rationale. Thresholds are enum-only: 65+ Bullish, 35 or lower Bearish, Neutral in between.
Data Source
News evidence comes from the GDELT Global Knowledge Graph (via BigQuery); TV evidence from the Internet Archive TV News Archive; video evidence from recent Bullish Gator video coverage. Azure OpenAI filters per-article relevance and serves as the holistic AI judge that produces the composite rating. Portions use data from The GDELT Project under open data terms. This page is informational analysis, not investment advice. See Financial Disclaimer.